Oramed Reports Third Quarter 2022 Financial Results
NEW YORK , Nov. 10, 2022 /PRNewswire/ — Oramed Pharmaceuticals Inc. (“Oramed” or the “Company”) (Nasdaq: ORMP) (TASE: ORMP) ( www.oramed.com ), a clinical-stage pharmaceutical company focused on the development of oral drug delivery platforms, today reported its financial results for the quarter
Oramed to Host Webinar Highlighting Detailed Safety and Efficacy Data from Its Positive Phase 2 Clinical Trial of ORMD-0801 for NASH
Webinar scheduled for Thursday, November 17, 2022 , at 11:00 a.m. EST Featuring key opinion leader discussion on current treatment landscape NEW YORK , Nov. 9, 2022 /PRNewswire/ — Oramed Pharmaceuticals Inc. (Nasdaq: ORMP) (TASE: ORMP) ( www.oramed.com ), a clinical-stage pharmaceutical company
Oramed Subsidiary Oravax Reports Positive Preliminary Phase 1 Data for its Oral Covid-19 Vaccine
Primary and secondary endpoints of safety and immunogenicity met Oral vaccine elicited a potentially protective IgG response with significant seroconversion from baseline Trial shows proof of concept for oral delivery of vaccines using Oravax technology NEW YORK , Oct.
Oramed Reports Positive Top-Line Results from Phase 2 NASH Trial with its ORMD-0801, Oral Insulin Candidate
Primary endpoint met: ORMD-0801 was safe and well tolerated Secondary endpoint met: ORMD-0801 showed clinically meaningful reduction of liver fat from baseline at 12 weeks Strong evidence for treatment of NASH using Oramed’s oral insulin NEW YORK , Sept.
Oramed to Present at H.C. Wainwright 24th Annual Global Investment Conference
NEW YORK , Sept. 6, 2022 /PRNewswire/ — Oramed Pharmaceuticals Inc. (Nasdaq: ORMP) (TASE: ORMP) ( www.oramed.com ), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, announced today that Chief Executive Officer Nadav Kidron will present an in-person
Oramed Reaches 50% Enrollment in its Second Phase 3 Oral Insulin Trial
- ORA -D-013-2 is the second of two Phase 3 trials under FDA protocol - ORA -D-013-1, the larger of the two trials, completed enrollment with top line data expected January 2023 NEW YORK , July 26, 2022 /PRNewswire/ — Oramed Pharmaceuticals Inc. (NASDAQ: ORMP) (TASE: ORMP) ( www.oramed.com ), a
Oramed to Present at the Upcoming Canaccord Genuity Annual Growth Conference
NEW YORK , July 11, 2022 /PRNewswire/ — Oramed Pharmaceuticals Inc. (Nasdaq: ORMP) (TASE: ORMP) ( www.oramed.com ), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, announced today that it will present an in-person company overview and share the
